From the ∗Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology
†Division of Surgical Oncology, Department of Surgery
‡Jonsson Comprehensive Cancer Center
§Division of Thoracic Surgery, Department of Surgery
∥Department of Pathology and Laboratory Medicine, David Geffen School of Medicine
¶Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
Received for publication May 14, 2020; revision accepted June 8, 2020.
Conflicts of interest and sources of funding: J. Calais is a consultant for Progenics Radiopharmaceuticals, Radiomedix, Blue Earth Diagnostics, Janssen Pharmaceuticals, and Curium Pharma. Consulting activities are outside of the submitted work. He is the recipient of grants from the ERF-SNMMI (2019–2021 Molecular Imaging Research Grant for Junior Academic Faculty), the Philippe Foundation Inc (New York), and the ARC Foundation (France) (International Mobility Award SAE20160604150). J. Czernin is a founder and board member and holds equity in Sofie Biosciences and Trethera Therapeutics. Intellectual property patented by the University of California is licensed to Sofie Biosciences and Trethera Therapeutics. J. Czernin serves on the medical advisory board of Actinium and is a member of the VISION trial steering committee, a clinical trial sponsored by Endocyte. J. Czernin is the recipient of a grant from the Prostate Cancer Foundation (2017 and 2019 Challenge Awards, 17CHAL02; 19CHAL02) and from the Johnson Comprehensive Cancer Center NIHNCI Cancer Center Support Grant (P30 CA016042). The other authors have none declared.
Correspondence to: Jeremie Calais, MD, MSc, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, 200 Medical Plaza, Suite B114-61, Los Angeles, CA 90095. E-mail: [email protected].
